Introduction {#S-1}
============

Scale of Suicide Problem {#SS1-1}
------------------------

In 1984, the member states of the World Health Organization's (WHO) European region highlighted suicide reduction as one of their prime health policy goals ([@c33]). More than 58,000 people die by suicide in the European Union every year -- one of the highest suicide rates in the world ([@c59]). Almost 900,000 lives are lost annually through suicide worldwide, constituting 1.5% of the global burden of disease ([@c33]). Nonfatal suicidal acts are believed to occur at least 10 times more frequently than fatal suicides ([@c41]). The economic costs of suicide are also high, with estimates in Ireland and Scotland suggesting average costs of EUR 1.5 million per completed suicide ([@c29]; [@c36]). These factors make suicide a major public health concern.

Depression as a Key Risk Factor for Suicide {#SS1-2}
-------------------------------------------

One European study has shown that many suicides occur in the context of psychiatric illness, with a population-attributable risk for lifetime suicide attempts put at 28% in major depressive disorder (MDD) ([@c4]). This underlines the importance of effective recognition and treatment. According to a WHO study ([@c33]), depression tops the list of disorders contributing to the global burden of disease. Future projections expect it to account for a growing share of the European burden of disease. Despite the availability of effective treatments, only about 21% of primary care patients with MDD receive optimal care ([@c3]; [@c13]). A number of factors are to blame for the underrecognition and consequent undertreatment of depression. These include deficits in primary care, such as inadequate knowledge about diagnosis and treatment ([@c51]), competing demands ([@c46]) and negative public and professional attitudes ([@c6]; [@c10]; [@c17]). Further causes are mental health illiteracy in depressed people ([@c27]), reluctance to seek help (in part due to fear of stigmatization) and poor treatment compliance ([@c19]). Programs to reduce suicide rates have been implemented ([@c14]; [@c47]; [@c59]), some of which appear to be more effective than others.

Synergistic Effects of Individual Activities Within Multilevel Interventions {#SS1-3}
----------------------------------------------------------------------------

Several reviews indicate that multilevel interventions should be the strategy of choice for suicide prevention ([@c2]; [@c34]; [@c45]). Evaluation of multilevel strategies and their components is a sine qua non for understanding their effectiveness, but little research has been done as yet. Multilevel strategies target several populations or several levels within healthcare systems, such as public health or primary care, or they include interventions with more than one focus, such as pharmacotherapy and psychotherapy. Key effective elements in such strategies must be identified, and additional evidence-based interventions need to be found for possible inclusion. As policymakers require up-to-date information that is readily translatable into practice, evaluation research should take place on a periodic basis.

It is also important to be aware of any synergistic potentials in multilevel interventions, as synergistic combinations ought to be part of recommended best practices. Positive synergistic effects occur where the effects of the combined interventions are more than the sum of the two (or more) parts. Synergism could be crucial to creating a critical impact in multilevel interventions. No systematic reviews are available so far that identify such positive synergistic elements.

Our assessment of systematic reviews of best practice therefore serves to identify evidence-based interventions that might be included as key elements in multilevel strategies for suicide prevention, and to identify potentials for synergism between such elements.

Method {#S-2}
======

Design {#SS1-4}
------

The focus of our review required us to obtain systematic reviews exploring different aspects of suicide prevention, levels of interventions and target populations. Our approach was systematic in its methodology, risk-of-bias assessment, data extraction methods, and reporting ([@c12]).

Procedure {#SS1-5}
---------

In 2008, a European Union-funded FP7 project entitled Optimizing Suicide Prevention Interventions (OSPI) ([@c24]), building on the work of the European Alliance Against Depression (EAAD) ([@c23]), began preparations for an optimal suicide prevention program in four European countries (Germany, Hungary, Ireland, and Portugal). One of its initial activities was to establish the best-practice interventions needed for inclusion. After consulting with OSPI partners to define aims and objectives, our working group set out to conduct its review of systematic reviews of effective suicide prevention interventions, defining the search terms and selection criteria in accordance with the PRISMA guidelines ([@c39]). After analysis and synthesis, we summarized core elements of successful best practices. Levels of evidence were graded using criteria set by the Oxford Centre for Evidence-Based Medicine (CEBM) ([@c43]).

Eligibility Criteria, Information Sources, Search {#SS1-6}
-------------------------------------------------

Potentially eligible reviews were identified by searching Pubmed/Medline, the Cochrane Database, and the Database of Abstracts of Reviews of Effectiveness (DARE) at the British National Health Service's Centre for Reviews and Dissemination; the latter is a database of systematic reviews, including Cochrane reviews. We used medical subject heading (MeSH) terms and free text terms for suicid\*, prevent\* and review\*. As an additional method of review identification, we checked the reference lists of selected articles to detect any missed studies, using the snowballing technique. We also made a hand search of key authors. Working group members checked their personal files for relevant publications and experts were consulted to uncover additional reviews not yet found. The search confined itself to the time frame from January 1964 to January 2011. No language or geographical restrictions were imposed.

Study Selection, Data Collection Process {#SS1-7}
----------------------------------------

Our inclusion criteria specified systematic reviews evaluating strategies to prevent suicidal behavior which focused on two or more levels of intervention or two or more target populations. Reviews were considered systematic if, according to their literature review protocol, they conducted a systematic search and reported the findings in line with the QUORUM ([@c39]) or PRISMA ([@c40]) guidelines. In the first stage of selection, three reviewers (VP, SR, and AT) evaluated whether each study met the inclusion criteria mentioned above on the basis of the title and abstract of the article. The reviewers worked independently and had the same level of seniority. Studies that clearly did not satisfy the criteria were excluded. If a study seemed eligible for inclusion or in case of doubt, the full text was retrieved. In the second stage, the same reviewers independently assessed the full articles. Disagreements regarding inclusion status were resolved by discussion between reviewers. If an agreement could not be reached the study was to be excluded. No study had to be excluded because of lack of consensus. In a third stage, the working group and other OSPI members were consulted to identify any missing reviews.

Risk-of-Bias Assessment {#SS1-8}
-----------------------

Risk of bias was determined by checking whether the systematic reviews included qualitative assessments of the primary studies they analyzed, according to generally accepted guidelines such as the Cochrane (Cochrane CC:DAN working group, 1998) or CEBM ([@c43]) quality criteria. If a review did not fulfill these criteria, it was to be excluded. The risk-of-bias determinations were made by a fourth assessor (CFC), who consulted the OSPI partners. No study had to be excluded.

Summary Measures {#SS1-9}
----------------

Interventions had to be described in sufficient detail to enable us to classify them as suicide-prevention programs. They were to focus on more than one group of participants or mental disorders, or have been performed on at least two levels. The focus could be on preventing either suicides or suicide attempts. Outcome measures were to include the impact of interventions on the number of completed or attempted suicides.

Synthesis of Results {#SS1-10}
--------------------

After consultation with OSPI partners, it was agreed to analyze the reviews systematically, including identification of: The patient or participant groups and the mental disorders targeted by each intervention;The interventions and their effect sizes;Whether attempts were made to assess synergistic effects;Whether reviews came to similar conclusions about recommendable prevention strategies.

We (DV, CFC) then formulated recommendations for best practices based on the outcomes of these analyses, after securing input from OSPI partners. Results were summarized in a data extraction table ([Table 3](#tbl3){ref-type="table"}).

Results {#S-3}
=======

Study Selection {#SS1-11}
---------------

The search strategy yielded 2114 citations, 6 of which ([@c11]; [@c26]; [@c32]; [@c34]; [@c44]; [@c50]) were reviews satisfying our PRISMA-based ([@c39]) inclusion criteria. This process is represented in [Figure 1](#fig1){ref-type="fig"}. The reviewers were consistent in their decision to include all the systematic reviews in the qualitative synthesis. Five systematic reviews were identified by the team of reviewers, and one systematic review ([@c32]) was added after consultation with the working group and members of the OSPI Consortium. Also, for this additional review, all reviewers were consistent in the evaluation that the study met the eligibility criteria for inclusion.

Characteristics of the Analyzed Studies {#SS1-12}
---------------------------------------

Study designs and risk of bias are indicated in [Table 1](#tbl1){ref-type="table"}. All six selected reviews met our quality criteria; none of the selected reviews had to be excluded.

All strategies involved public health and/or clinical approaches aiming at suicide prevention either in general populations or in specific subgroups (including children and adolescents, previous suicide attempters and psychiatric patients). As the reviews focused on differing modes of intervention, there was no substantial overlap between the primary studies analyzed. The reviews covered universal and indicated approaches, ranging from public-health interventions targeting whole communities to individually focused psychopharmacological or psychotherapeutic interventions.

Synthesis of Results {#SS1-13}
--------------------

The working group first examined the interventions described in the reviews to identify which intervention levels and target populations were included. The results are described below and summarized in [Table 2](#tbl2){ref-type="table"}. If potential synergies were detected within particular strategies, that was indicated. Levels of evidence were determined. The data extraction table indicates the effectiveness of the identified interventions, including any potential synergistic effects we detected. The reviews themselves made no explicit evaluations of synergistic effects within multilevel interventions.

A list of identified best practices is provided in [Table 3](#tbl3){ref-type="table"}. Multilevel strategies target several populations or several levels within healthcare systems, such as public health or primary care, or they include interventions with more than one focus, such as pharmacotherapy and psychotherapy.

Intervention Levels {#SS1-14}
-------------------

### Primary Care {#SS2-1}

At the primary-care level, an improvement in depression recognition and suicide risk evaluation by GPs was found to be an important component of suicide prevention (see [Table 3](#tbl3){ref-type="table"}) ([@c32]; [@c34]). The recent systematic review by [@c26] has confirmed that increased antidepressant prescribing rates and significantly reduced suicide rates are reflected in studies examining depression recognition and treatment in relation to suicidal behavior after GP education programs. The mechanism here is generally assumed to involve improved recognition and treatment of underlying mental disorders ([@c34]). Psychiatric disorders are present in at least 90% of suicides, and up to 80% of such cases have gone untreated at the time of death ([@c33]). Studies also indicate that pharmacological treatment can contribute significantly to decreased suicidal risk in individuals with various mental disorders ([@c34]). The new generation of psychotropics (selective serotonin reuptake inhibitors, SSRIs; serotonin-norepinephrine reuptake inhibitors, SNRIs; dual-action antidepressants; high-potency anxiolytics; atypical antipsychotics) has the potential for safe and effective treatment either in the short or the long term. Many different forms of psychotherapy were evaluated in reviewed studies, yet with one exception (cognitive-behavioral therapy) none were to be found successful in reducing suicide risks ([@c34]). The review by [@c50] reported a highly significant overall effect of cognitive-behavioral therapy in curbing suicidal behavior. Subgroup analysis revealed a significant treatment effect for adults (but not for adolescents) in comparison to treatment as usual or minimal treatment, but not in comparison to other active treatment; the authors caution against overoptimistic interpretation and warn of possible publication bias.

### Population Level: General Public and Gatekeepers {#SS2-2}

In examining public awareness as a level of preventive intervention, [@c34] note that public education campaigns aim mostly at improving suicide risk recognition and help-seeking behavior by fostering a clearer understanding of causes and risk factors for suicidal behavior, particularly mental illness. Public awareness approaches also seek to reduce the stigmatization of mental illness and suicide. Although awareness raising is a widely employed strategy, systematic reviews yield conflicting results in terms of attempted and completed suicides. [@c34] reported no detectable effects of public awareness on the primary outcome measure of reduced rates of suicidal acts -- and also not on intermediate measures like increased treatment seeking or antidepressant use. This was possibly because educating journalists and establishing of media guidelines for reporting suicide have had mixed results ([@c18]; [@c34]). [@c11] reported mixed overall results and suggested that the sustainability of outcomes should be evaluated. They also believe that more robust outcomes might be achieved by combining the public awareness intervention with other interventions at regional levels. [@c26] reported clear and significant reductions in attempted and completed suicides in several studies evaluating the training of gatekeepers, but they emphasize that such interventions were generally part of more complex strategies, making it difficult to ascertain their specific impacts.

### High-Risk Groups {#SS2-3}

In public health terms, an approach to suicide prevention outlined by [@c34] could be used to screen for people at risk of suicidal behavior and depression. Thus far, no published studies have evaluated the effectiveness of screening for suicide risk in adults or children and adolescents in primary care ([@c44]; [@c60]). Although a review of depression screening studies did not find evidence that isolated routine screening in primary care improves depression care in the absence of adequate follow-up care ([@c16]), there is enough evidence of improved depression outcomes if such resources are available, or when treatment is offered only to those individuals with scores above certain thresholds ([@c16]). Given these findings, it may be premature to include screening in primary-care settings as a best-practice component of suicide prevention. Yet research to improve case finding of at-risk individuals is certainly indicated; viable instruments like the Patient Health Questionnaire (PHQ-9) ([@c31]) are available, as are effective treatments ([@c7]).

### Restricting Access to Means of Suicide {#SS2-4}

Means restriction was identified by [@c34] as a further important element in suicide prevention. Suicide deaths as a consequence of methods with high lethality have been shown to decrease after access to them is restricted ([@c18]; [@c34]; [@c45]).

Targeted Populations {#SS1-15}
--------------------

### Psychiatric Patients {#SS2-5}

Psychiatric patients are most definitely one of the high-risk groups for suicidal behavior. Consequently, as pointed out by [@c34], the improvement of acute, continuation, and maintenance treatment, including psychiatric hospitalization, for people with recurrent or chronic psychiatric disorders (and particularly those who have already attempted suicide) has preventive potential. According to the review by [@c32], telephone support and other forms of contact and emotional support provided to people known to have engaged in suicidal behavior or suicidal ideation significantly mitigates their risk of suicidal behavior.

### Children and Adolescents {#SS2-6}

Suicide prevention programs for children and adolescents have had mixed results in terms of effectiveness and impact. For children in particular, there is some limited evidence that certain interventions -- including pharmaceutical, psychotherapeutic, behavioral and staff- or parent-training initiatives -- may be effective in reducing suicidal behavior and ideation. Studies show that while knowledge about suicide improves, there are both beneficial and harmful effects in relation to help-seeking, attitudes, and peer support. School curriculum-based programs enhance knowledge and improve attitudes about mental illness and suicide, but there is insufficient evidence that they actually prevent suicidal behavior. Indeed, they may even disturb high-risk adolescents and make them more prone to harmful behaviors, especially if they do not afford direct access to care. It is suggested that awareness raising combined with easier access to care may have synergistic effects, but this has yet to be confirmed in children and adolescents. Improving problem-solving and stress-coping abilities and resilience appear to enhance hypothesized protective factors, but the effects on suicidal behavior remain unevaluated ([@c34]).

### Older People {#SS2-7}

As noted by [@c32], treatment studies of SSRIs in older adult populations report reductions in attempted suicides following psychopharmacological interventions. The authors also point to reductions in suicide after the provision of palliative care to older people with cancer. Community-based support programs for older people in rural areas have also reportedly decreased suicide incidence. A recent US Food and Drug Administration analysis of suicidality and antidepressants in adults is worth noting too, as it found some signs of protective effects of SSRIs in people older than about 25, but not in younger people ([@c30]).

### Ethnic Minorities {#SS2-8}

Successful interventions for ethnic minorities identified in the systematic review by [@c32] include ethnically tailored, community-wide public health programs; video-focused educational interventions to modify family expectations regarding self-harm; and school-based initiatives to train school staff and pupils to respond to suicidal crises.

Discussion {#S-4}
==========

Findings {#SS1-16}
--------

This review of six systematic reviews on suicide prevention yielded evidence for the actual or potential effectiveness of several types of preventive interventions: (1) the training of GPs in the recognition and treatment of mental disorders, especially unipolar and bipolar depression; (2) awareness campaigns, provided that a clear fast track to treatment is available; (3) the training of gatekeepers and community facilitators in recognizing suicidality and helping at-risk people to access appropriate services; (4) improvement of healthcare services targeting people at risk, including organizational measures such as making adequate inpatient and outpatient aftercare available to people who have attempted suicide; (5) the training of journalists in responsible reporting about suicide or the imposing of media blackouts; (6) restricting public access to lethal means of suicide.

The last of these measures could be highly effective and should probably be part of any multilevel intervention; wide variations in outcomes might be expected, however, as the measures taken may differ among countries ([@c55], [@c54]). If national multilevel approaches are adopted, it is crucial to ensure that adequate suicide surveillance data are brought to the attention of policymakers on a regular basis, enabling them to devise responsive measures. There might be scope here both for national or pannational measures, such as limiting package sizes for medications, and for more locally specific actions, such as revising laws on the accessibility of firearms in certain jurisdictions.

None of the studies we reviewed here included outcome measures to evaluate synergistic effects of the separate types of interventions analyzed. As seen in [Table 2](#tbl2){ref-type="table"}, some synergistic mechanisms were alluded to, but they were not evaluated as such. Some potentially beneficial suggestions were made, such as Dumesnil's ([@c11]) proposal to combine interventions in specific regions to obtain better outcomes and Mann's ([@c34]) reference to complex interventions. The systematic reviews thus provide no firm evidence that multilevel interventions are a more effective approach, and more research on them is urgently needed.

The literature and findings so far suggest that an integrated strategy that includes community facilitator training, GP training and ready access to mental healthcare offer the greatest potential for synergism. These might also be combined with more sociological strategies, such as policies targeting the media or restricting access to means for self-harm. One local intervention program for which there is some evidence of effectiveness was the Nuremberg Alliance Against Depression (NAD). This multilevel approach showed a clear effect in terms of reducing suicides and suicide attempts, and it also improved the care of depressed patients, in a prepost design ([@c21]). Comprehensive, integrated approaches like these, however, have not yet been evaluated in a controlled design, although attempts to do so are currently underway ([@c35]). On the basis of these positive outcomes, the NAD approach was rolled out across Europe in the European Alliance Against Depression (EAAD), which resulted in the implementation of a four-level, community-based intervention in 17 countries ([@c20]; [@c21]). This includes (1) cooperation with general practitioners and pediatricians, (2) public awareness campaigns and cooperation with local media, (3) cooperation with local actors such as healthcare professionals, geriatric care providers, counselors, and religious leaders, who play important roles as multipliers in disseminating knowledge about depression, particularly to children and adolescents, (4) targeted interventions for high-risk groups such as young people in adolescent crisis and people who have attempted suicide. All four types of interventions are being implemented concurrently in a multilevel approach. Independent thereof, several countries also developed and implemented systematic multilevel strategies involving national-level depression treatment programs ([@c8]; [@c25]; [@c28]; [@c38]; [@c53]) or national action plans for suicide prevention ([@c49]; [@c56]; [@c9]; [@c48]; [@c57]; [@c5]; [@c52]; [@c58]). These are based on regional or national networks and are multidisciplinary in nature.

Strengths and Limitations of This Review {#SS1-17}
----------------------------------------

Among the limitations is that we were unable to generate effect sizes because of the lack of meta-analyses in the original systematic reviews. We could therefore only describe the evidence. Yet all evidence points in the same direction: Suicide prevention interventions can be effective at several levels. Although researchers have pointed out the methodological difficulties of demonstrating effects of an intervention on suicidal behavior in a controlled design, the reviews examined here highlighted several types of interventions that appear to reduce suicide rates.

Another key limitation of our review is its pragmatic reliance on studies identified in previous systematic reviews. Some new primary studies may have thereby been missed. Limitations in the scope of the databases examined may have also caused us to overlook reviews focusing on infrastructure change, such as improvements in bridge and railway safety. We hope to have minimized such limitations by using DARE and Cochrane, high-quality databases on systematic reviews. A further limitation is that the studies examined here were mostly conducted in Europe, thus potentially limiting the relevance for other regions.

Although several of the systematic reviews discussed here advocated multilevel approaches, they made no systematic attempt to identify possible synergies between interventions. Their evidence does suggest that preventive interventions at several levels can be effective against suicidal behavior. Some reviews suggested combinations of interventions with potential synergistic effects. The relative impact of interventions within multilevel approaches still needs exploring.

On the basis of the evidence of effectiveness established so far, the strongest impact can probably be expected from GP training, facilitating access to care for at-risk people and restricting access to means of suicide. Obviously this is a topic for future research. Another topic would be to explore approaches that would work in countries where GPs do not have gatekeeping functions, that is, where primary care plays a less prominent role and individuals can directly access specialist care; a specific question is who needs to be trained in countries without primary care-led systems.

It is also worth noting that the systematic reviews discussed here do not take account of the recent debate about associations between SSRI use and rising or falling suicide rates, a discussion that has only really emerged in recent years; [@c34] point out the need for further research on this issue.

Research Implications {#SS1-18}
---------------------

It follows from our analysis that groups at risk of suicide would be more likely to receive adequate mental healthcare if a regional or supraregional approach were adopted that combines awareness campaigns in schools and in the general public with the training of community facilitators in closest contact with at-risk groups. Organizational interventions such as collaborative care arrangements ([@c1]; [@c7]) would facilitate entry into care ([@c8]), and GP training would improve both the recognition of risk and the quality of care. Restricting access to potentially lethal means for committing suicide might have an added beneficial effect. Concurrent awareness campaigns might encourage individuals who are contemplating suicide to seek help. A combined approach should thus be more effective than the sum of its parts. In view of the lack of research so far into synergistic effects, further evaluation is needed on strategies that combine these interventions. One way to produce synergistic effects would be to begin with a strong public awareness element, which might later facilitate cooperation with GPs and other multipliers. Yet awareness raising may only be useful if support is provided in finding help. An example will show how synergistic effects might be generated. A public awareness campaign motivates a depressed individual to discuss depressive symptoms with a GP, which in turn motivates the GP to obtain more training on the issue. Such training would be available under the multilevel approach. Yet training alone may not be sufficient. Judging from a recent debate, GPs are still unable to reliably identify and treat depressed patients despite decades of training on the issue. They may therefore need additional support above and beyond such training. In a multilevel approach, the public awareness campaign, supplemented by materials such as a waiting-room poster on depression, may make it easier for a GP to suggest a possible diagnosis of depression to patients who have come for other reasons, and to discuss and start treatment. Another multilevel strategy would be to combine such a public campaign with secondary prevention measures such as screening for and helping high-risk individuals and providing aftercare for individuals bereaved by suicide, as is now being evaluated in Japan ([@c42]).

Screening for disorders like depression might indeed be useful. Detection and treatment of moderately severe cases of major depressive disorder in primary care settings has proved effective in reducing depressive symptoms, provided appropriate resources are available to improve the quality of routine care ([@c15]). Screening for other conditions such as psychotic disorders has not yet been shown to be effective. Thus, the specific effectiveness of screening in reducing suicide rates in the public health domain has yet to be established and requires further research.

Careful, well-conducted research is needed, as emphasized in the WHO study on the mental health treatment gap. It explicitly highlights suicide prevention strategies that combine interventions from inside and outside the health sector and calls for an innovative, comprehensive multisectoral approach, including health sectors as well as nonhealth sectors such as education, labor, police, justice, religion, law, politics, and media.

Beyond measuring the impact of such strategies on suicide rates, future studies of multilevel interventions must also assess the cost-effectiveness of proposed measures and their effects on intermediate outcomes, such as rates of GP-diagnosed major depression and antidepressant prescription rates. The ongoing OSPI study provides an opportunity to address these questions ([@c24]).
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###### Risk of bias

![](cri_32_6_319_tbl1a){#tbl1a}

  Article                 Specific research question                                                                                                                                                                            Appropriate search   Specified search terms   Inclusion/exclusion criteria   Clarity of individual study findings   Analysis of study findings   Valid conclusions
  ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------ ------------------------------ -------------------------------------- ---------------------------- -------------------
  [@c34]                  To examine evidence for the effectiveness of specific suicide-prevention interventions and make recommendations for future prevention programs and research                                           Yes                  Yes                      Yes                            Yes                                    Yes                          Yes
  Leitner et al. (2008)   To provide a comprehensive overview of the known effectiveness of interventions to prevent suicide, suicidal behavior, and suicidal ideation, both in key risk groups and in the general population   Yes                  Yes                      Yes                            Yes                                    Yes                          Yes
  [@c26]                  To review the state of evidence on gatekeeper training for suicide prevention and propose directions for further research                                                                             Yes                  Yes                      \*                             No                                     \*                           \*
  [@c11]                  To summarize data on the impact and effectiveness of campaigns for depression and suicide awareness                                                                                                   Yes                  Yes                      Yes                            Yes                                    Yes                          Yes
  [@c60]                  To assess the health effects of routine primary care screening for MDD in children and adolescents aged 7--18                                                                                         Yes                  Yes                      Yes                            Yes                                    Yes                          Yes
  [@c50]                  To assess whether cognitive-behavioral therapy reduces suicidal behavior                                                                                                                              Yes                  Yes                      Yes                            Yes                                    Yes                          Yes

###### Suicide prevention strategies identified in systematic reviews and their effects on outcomes in terms of attempted or completed suicides

![](cri_32_6_319_tbl2a){#tbl2a}

![](cri_32_6_319_tbl2b){#tbl2b}

  Author of systematic review/Number of studies                                                                                                                                                          Level of intervention                                                                          Target populations                               Effect size                                                                                                                                                          Highest level of evidence   Synergism
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------------
  [@c34]                                                                                                                                                                                                 Awareness and education                                                                        General public                                   No detectable effect                                                                                                                                                 2B                          Mentioned, but no assessment
  SRs *n* = 10, RCTs *n* = 18, Cohorts *n* = 24, Ecological *n* = 41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                        GPs                                              Modest                                                                                                                                                               2B                          \*
                                                                                                                                                                                                                                                                                                        Gatekeepers                                      Modest                                                                                                                                                               2B                          \*
                                                                                                                                                                                                                                                                                                        Media                                            Modest                                                                                                                                                               2B                          \*
                                                                                                                                                                                                         Screening                                                                                      Adults in primary care                           No outcomes on attempted/completed suicide                                                                                                                           2A                          \*
                                                                                                                                                                                                         Pharmacotherapy                                                                                Adolescents                                      Inconclusive                                                                                                                                                         1A                          \*
                                                                                                                                                                                                                                                                                                        Adults                                           Modest effect in adults                                                                                                                                              1A                          \*
                                                                                                                                                                                                         Psychotherapy                                                                                  Not specified                                    Inconclusive                                                                                                                                                         1A                          \*
                                                                                                                                                                                                         Follow-up care after suicide attempts                                                          Suicide attempters                               Modest effect                                                                                                                                                        2B                          \*
                                                                                                                                                                                                         Restriction of means                                                                           Not specified                                    Modest effect                                                                                                                                                        2C                          \*
  [@c50])                                                                                                                                                                                                Individual cognitive-behavioral therapy                                                        Adults                                           Highly significant effect in reducing suicidal behavior when compared to minimal treatment or treatment as usual (but not when compared to other active treatment)   1A                          \*
  RCTs *n* = 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                        Adolescents                                      No effect                                                                                                                                                                                        
  [@c26]                                                                                                                                                                                                 Gatekeeper training for suicide prevention                                                     GPs                                              Rate decrease from 19.7 to 7.1 per 100,000                                                                                                                           2B                          \*
  Cohorts *n* = 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                         24% decrease in attempted and completed suicides                                                                                                                     2B                          \*
                                                                                                                                                                                                                                                                                                                                                         Lower rate (*ns*)                                                                                                                                                    2B                          \*
                                                                                                                                                                                                                                                                                                        Air force personnel                              33% relative risk reduction in suicide rate                                                                                                                          2B                          \*
                                                                                                                                                                                                                                                                                                        Adolescents                                      73% decrease in mean number of attempts                                                                                                                              2B                          \*
  [@c11]                                                                                                                                                                                                 Awareness campaigns                                                                            Media                                            No effect                                                                                                                                                            2B                          Mentioned, but no assessment
  Cohorts *n* = 2, RCTs *n* = 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                        Gatekeepers                                      No outcomes for suicide reduction                                                                                                                                    2B                          Mentioned, but no assessment
                                                                                                                                                                                                                                                                                                        General public                                   Reduced suicide rates in 1 of 9 programs                                                                                                                             2B                          Mentioned, but no assessment
  [@c60]                                                                                                                                                                                                 Primary-care screening with follow-up treatment for MDD (SSRI and/or psychotherapy)            Children and adolescents aged 7--18              No data describing health outcomes in screened and unscreened populations                                                                                            1A                          \*
  RCTs of screening and treatment vs no screening *n* = 0, Diagnostic accuracy studies *n* = 9, RCTs of treatment with SSRIs or psychotherapy *n* = 20, RCTs reporting adverse events of SSRIs *n* = 9                                                                                                                                                                                                                                                                                                                                                    
  Leitner et al. (2009)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  200 primary empirical studies, 37 systematic reviews                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                        Ethnic minority children                         Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         Community-wide health program                                                                  Community                                        Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                                                                                                                        Media                                            Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         Inpatient and outpatient treatment                                                             Depressed patients                               Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         SSRI, SNRI, dual-action antidepressants, high-potency anxiolytics, mood stabilizers, lithium   Bipolar and unipolar depressed patients          Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         SSRIs                                                                                          Depressed elderly                                Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         Atypical antipsychotics                                                                        Psychotic patients                               Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         Intermediate care service                                                                      People in contact with criminal justice system   Effect                                                                                                                                                               3A                          \*
                                                                                                                                                                                                         Restriction of means                                                                                                                            Effect                                                                                                                                                               3A                          \*

###### Key elements of best practice interventions for suicide prevention
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  ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  LEVEL 1. Cooperation with general practitioners (GPs) to improve their knowledge and abilities in detecting and managing suicide risks   
  Training content                                                                                                                         Use of screening tools for detecting depression and suicide risks, e.g., PHQ-9
                                                                                                                                           Information about treating depression and suicidal patients according to existing national guidelines
                                                                                                                                           Information about different forms of pharmacological treatment and their relation to decreased suicide risk
                                                                                                                                           Knowledge of populations vulnerable to suicide risk
  Training format                                                                                                                          Embedded in continuing medical education or professional supervision sessions
                                                                                                                                           Provided on a periodic basis
                                                                                                                                           3 to 4 sessions of up to 3 h
                                                                                                                                           Embedded in the GPs' primary care organizations (vital both to facilitate implementation and ensure sustainability)
                                                                                                                                           GPs engaged in planning the training
                                                                                                                                           Possibly with a basic component for a large group and secondary sessions in smaller groups with role plays
  Tools to facilitate GPs                                                                                                                  Telephone helpline providing psychiatric consultation for GPs
                                                                                                                                           Information materials for different vulnerable populations
                                                                                                                                           Guidelines containing options for referring patients at risk of self-harm to relevant local mental health services
  ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
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